Search

Search Constraints

You searched for: Author/Creator Oaknin, Ana

Search Results

11. 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. (20th October 2022)

12. 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. (20th October 2022)

13. 2022-RA-945-ESGO Antitumour activity of dostarlimab by PD-L1 and tumour mutation burden in patients with mismatch repair deficient and proficient tumours in the GARNET trial. (20th October 2022)

14. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

15. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016)

16. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

17. 385 Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study. (4th December 2020)

18. 39/#452 Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the garnet study. (4th December 2022)

19. 392 Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study. (4th December 2020)

20. 518 Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers. (4th December 2020)